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Monocytes and cells of the dendritic cell
lineage circulate in blood and eventu-
ally migrate into tissue where they fur-
ther mature and serve various func-
tions, most notably in immune defense.
Over recent years these cells have been
characterized in detail with the use of
cell surface markers and flow cytom-
etry, and subpopulations have been de-
scribed. The present document pro-
poses a nomenclature for these cells
and defines 3 types of monocytes (clas-
sical, intermediate, and nonclassical
monocytes) and 3 types of dendritic
cells (plasmacytoid and 2 types of my-
eloid dendritic cells) in human and in
mouse blood. This classification has
been approved by the Nomenclature
Committee of the International Union of
Immunological Societies, and we are
convinced that it will facilitate communi-
cation among experts and in the
wider scientific community. (Blood.
2010;116(16):e74-e80)
Introduction
The nomenclature of monocytes and dendritic cells (DCs) in blood
has become quite confusing because of the use of different
antibodies for their identification, and due to the existence of
several subpopulations, and to the swapping of nomenclature
between species. To resolve this, a group of experts drafted a
nomenclature proposal under the auspices of the International
Union of Immunological Societies (IUIS) and the World Health
Organization. This proposal was discussed at a workshop orga-
nized by the Dendritic Cells for Novel Immunotherapies (DC-
THERA) European Network of Excellence and the European
Macrophage and Dendritic Cell Society in Brescia, Italy, in 2008.
After the meeting, the amended proposal was extensively dis-
cussed, and finally the nomenclature, presented in this paper, was
agreed by the panel as a current consensus, acknowledging that it
may well require review in the future.
The nomenclature follows the general rule of giving species and
tissue a nonpreemptive name and informative markers. At this
stage the nomenclature proposal refers to the steady state; its
application to inflammatory conditions has to be done with care,
because inflammation may perturb the expression of markers
independent of changes in the composition of cell populations.
Knowledge about cells in the blood compartment, because of the
ready access, is greatest in humans, whereas fewer studies are
available for mouse and rat. Because of that, humans take the lead
in this nomenclature proposal. We propose herein the terminology
classical, intermediate, and nonclassical for the different types of
blood monocytes, and for cells of the DC lineage we suggest the
terms plasmacytoid and myeloid blood DCs, with 2 distinct types
for the latter. These names are combined with informative cell-
surface markers.
Monocytes
Early studies have shown that bone marrow precursors give rise to
monocytes in blood, which circulate for a few days before they
migrate into tissue where they develop into different types of
macrophages.1 Cells of this lineage are collectively referred to as
mononuclear phagocytes or monocytes/macrophages. They are
multifunctional with roles in homeostasis, immune defense, and
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tissue repair, and they were shown to express an extremely diverse
transcriptome.2 In humans, monocytes were initially defined on the
basis of morphology and cytochemistry (monocyte-specific ester-
ase) and later by flow cytometry that was based on light scatter
properties and on cell-surface markers such as CD14. This
technology enabled the identification of a CD16 subpopulation,3
which is characterized by higher major histocompatibility complex
(MHC) class II expression and after stimulation by Toll-like
receptor (TLR) ligands by higher tumor necrosis factor (TNF)
production.4-6 In addition, these cells were shown to expand in
inflammatory diseases.7,8 The classical CD16 monocytes and
these CD16 cells were shown to share morphology, cytochemis-
try, and many cell-surface markers. The more recent approach of
expression profiling and hierarchical clustering has substantiated
the close relationship of the 2 types of cells.9,10 In addition,
monocytes with an intermediate phenotype between classical and
CD14lowCD16 monocyte subsets have been described. These are
found at low frequency, but they have unique features and expand
with cytokine treatment and in inflammation.11-17
It has been shown that monocytes can differentiate into DCs in
vitro and in vivo.18-22 Although monocytes, therefore, might be
addressed as DC precursors, the panel agreed that these cells still
are best called monocytes, because they are not exclusively
precursors of DCs but are also the precursors of macrophages.
The use of popular terms such as “inflammatory monocytes,” or
“proinflammatory monocytes” is not recommended because this
leads to confusion as the label inflammatory has been used for
different subpopulations in humans and mice. In addition, these
terms may prematurely ascribe functional attributes to cells based
on ex vivo studies while they largely remain to be functionally
characterized in vivo. Earlier, the main monocyte population in
humans has been called “classical monocytes,”4 and later it was
suggested to label the CD16 cells “nonclassical monocytes.”23
This approach has been adopted for monocytes in the present
nomenclature.
Human blood monocytes
For human blood monocytes a subdivision into 3 subsets, that is,
classical, intermediate, and nonclassical, is suggested (Table 1).
Because for the monocyte/macrophage system the term mono-
cyte is reserved for the cells in blood, it was felt that it is not
necessary to always use the label blood when referring to mono-
cytes. Classical monocytes are the cells known to hematologists for
a century as monocytes on the basis of structure, whereas the
somewhat smaller, nonclassical monocytes, which account for only
10% of all monocytes, were described only 20 years ago. There
appears to be a developmental relationship between these cells
(from classical by intermediates to nonclassical) in that, during the
course of an infection or with macrophage colony-stimulating
factor (M-CSF) treatment, there is an increase first of the intermedi-
ate cells followed by an increase of the nonclassical CD14CD16
monocytes.13 Here,  denotes an expression level that is  10-fold
above the isotype control and  is  100-fold above the isotype
control. With a gradual development from classical to nonclassical
monocytes, it may be difficult at times to determine the boundaries
between the subpopulations. As with any immunofluorescence
analysis, isotype controls are to be used for proper determination of
subpopulations.
The CD14 and CD16 markers have proven useful in many
studies in the literature, and their use is recommended for
determination of subpopulations. For human monocytes CD14 and
CD16 antibodies targeting different epitopes are available. For
CD14 we suggest the use of antibodies directed against the
lipopolysaccharide-binding domain and for CD16 those that bind
to the Fc-binding domain. To exclude granulocytes CD66b can be
helpful, but intracellular lactoferrin is also a robust marker for
exclusions of neutrophils.24 For exclusion of natural killer cells
CD56 is recommended, and staining for MHC class II expression
and for low-level CD4 on monocytes can also be helpful.
CD43, although showing a strong differential staining in mouse
monocytes subsets (see “Mouse blood monocytes”), gives only a
weak difference for the human subsets and is not recommended for
standard staining. CCR2/CD192 staining, however, distinguishes
human subsets very clearly, and there is also differential expression
in the mouse.25,26 CCR2 may well become a marker for definition
of subpopulations in the future, but its usefulness for this purpose
still needs further study.
Published evidence for further subsets includes proliferating
monocytes and 6-sulfo LacNAc and FcRI monocytes.27-31 Once
more information from different research groups is available, these
subpopulations can potentially be incorporated in this nomencla-
ture. Taken together, we recommend to subdivide human mono-
cytes into 3 subsets on the basis of the expression of CD14 and the
CD16 receptors (Figure 1). The classical monocytes show high
CD14 expression but no CD16 (CD14CD16), the intermediate
monocytes show a high level of CD14 together with low CD16
(CD14CD16), and the nonclassical monocytes express a low
level of CD14 together with high CD16 (CD14CD16; Table 1).
When the intermediate and the nonclassical monocytes are not
separately defined, then we propose to address them collectively as
CD16 monocytes.
Mouse blood monocytes
For mouse blood monocytes a subdivision into 3 subsets similar to
humans is proposed, that is, classical, intermediate, and nonclassi-
cal (Table 1).
Markers CD43 and Ly6C have proven to be informative with
respect to differential expression. Reagents detecting the
Gr-1 epitope, which is present on both Ly6C and Ly6G, are
available, but the use of specific anti-Ly6C antibodies is to be
preferred. In addition, models that use transgenic mice have been
highly informative for definition of monocyte subpopulations such
as mice with differential expression of CX3CR1-promoter–driven
marker genes.26,32,33 Such studies on chemokine receptor expres-
sion have shown that the classical monocytes in the mouse are
CCR2high and CX3CR1low, whereas the nonclassical monocytes are
CCR2low and CX3CR1high.
Because none of the markers used for subset definition
is monocyte specific, additional markers such as CD11b or
CD115 (M-CSF receptor) have been used to define monocytes as
such. The M-CSF receptor has been used because it clearly
discriminates monocytes from granulocytes. The disadvantage of
this marker is that the CD115 protein can be cleaved under
Table 1. Nomenclature of blood monocytes
Human Mouse*
Classical CD14CD16 monocytes Classical Ly6C CD43 monocytes
Intermediate CD14CD16 monocytes Intermediate Ly6C CD43 monocytes
Nonclassical CD14CD16 monocytes Nonclassical Ly6C CD43 monocytes
The CD markers given are considered most appropriate at this time. They may be
superseded by superior reagents in the future. The  denotes an expression level that
is 10-fold above the isotype control and  is 100-fold above the isotype control.
*Additional markers have to be used to define the cells under study as monocytes
(see text).
NOMENCLATURE OF MONOCYTES AND DCs IN BLOOD e75BLOOD, 21 OCTOBER 2010  VOLUME 116, NUMBER 16  personal use only.
For at Helmholtz Zentrum Muenchen Zentralbibliothek on October 25, 2010. www.bloodjournal.orgFrom 
conditions of inflammation. This can be obviated with the use of
M-CSF-R promoter–driven green fluorescent protein, but, unfortu-
nately, such animals show strong green fluorescent protein expres-
sion also in granulocytes.34 In addition, although CD14 is ex-
pressed by mouse monocytes, the signal is too weak to serve as a
monocyte marker in this species. Therefore, a single optimum
defining marker for mouse monocytes is still needed.
Cell-depletion studies have shown a developmental relationship
between classical and nonclassical monocytes35 in that the nonclas-
sical monocytes in mouse blood are more mature and derived from
the classical monocytes. Because this relationship is also found
in humans, these data support the concept that the nonclassical
Ly6CCD43 monocytes in mouse blood are homologous to
human nonclassical CD14CD16 monocytes. Furthermore,
studies on cytokine expression after stimulation with TLR ligands
have shown higher levels of TNF protein per cell in the nonclassi-
cal monocytes compared with the classical monocytes both in
humans and mouse.4,36 Similar to humans intermediate cells in the
mouse were shown to have unique features.37
In addition, in the mouse nonclassical monocytes show lower
CD14 and higher CD16 staining compared with the classical
monocytes,38 further supporting the concept that the nonclassical
monocytes in humans and mouse are homologous cell types.
Finally, transcriptional profiling of mouse subsets has provided
further evidence for the homology of the nonclassical blood
monocytes in humans and mouse.38,39
Again, it may be difficult to determine the boundaries between
the mouse monocyte subpopulations, especially when it comes to
the intermediate cells. Unique markers for these intermediate cells
are required. Taken together, we suggest a subdivision of mouse
monocytes similar to humans on the basis of the expression of
Ly6C and CD43. The classical monocytes show high Ly6C
expression and low CD43 (Ly6CCD43), the intermediate
monocytes show a high level of Ly6C together with high CD43
(Ly6CCD43), and the nonclassical monocytes express a low
level of Ly6C together with high CD43 (Ly6CCD43; Table 1).
For rat blood monocytes a few groups have addressed subpopu-
lations.40-42 Although there is evidence for heterogeneity, a nomen-
clature for blood monocytes subsets in the rat is considered
premature at this point in time. Note, however, that also in the rat,
CD43 is differentially expressed among monocyte subsets, and
transfer of CD43 monocytes gives rise to CD43 cells in vivo.42
This suggests a similar developmental relationship between subsets
as has been observed in humans and mouse. However, a definite
description of rat monocyte subsets awaits further study with an
appropriate set of markers and with functional analyses. In any
case, we suggest that the terms “classical” and “nonclassical”
might be used in other species besides human and mouse when the
appropriate counterparts have been identified.
Blood DCs
DCs were first identified as a discrete cell type in lymphoid organs
in the mouse.43 Cells assigned to the DC lineage in blood have been
characterized mainly in humans with a few studies available for the
mouse and no data for the rat. Again, the human system takes the
lead when it comes to nomenclature for cells in blood. The panel
classical CD14++ CD16-
intermediate CD14++ CD16+
nonclassical CD14+ CD16++
myeloid CD1c+
plasmacytoid CD303+
myeloid CD141+
Human blood monocytes
Human blood DCs
CD16-positive
monocytes
Figure 1. Nomenclature of monocytes and DCs in blood. The 6 types
of cells are shown with different symbols, which represent the crucial
markers of the respective cells. Blue hook indicates CD14; red square
flag, CD16; green flag, CD303; blue flag, CD1c; red diamond flag,
CD141. A higher number of a given symbol indicates a higher density of a
given receptor. The arrows in the upper portion represent the developmen-
tal relationship. This does not necessarily indicate that development is
actually occurring in the blood compartment. The location of the nonclas-
sical monocytes closer to the vessel wall is to indicate that these cells
preferentially localize to the marginal pool, a concept supported by the
intravital microscopic data for the mouse homologue. The 2 types of
myeloid DCs are depicted closer to each other because both are closer
related to each other compared with the plasmacytoid DCs.
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recognizes the difficulty of defining a DC compared with a
monocyte/macrophage because these 2 cell types are closely
related, as evidenced by the findings that blood monocytes can
differentiate into DCs18-22 and that DCs from human blood can
differentiate into macrophages.44 In addition, the expression of
individual markers such as the commonly used CD11c is not
restricted to DCs; 90% of human monocytes and approximately
40% of mouse monocytes are CD11c,35,45 and alveolar macro-
phages in the mouse are also CD11c.46 In fact, it is very difficult at
present to identify a single marker that can be used to clearly assign
a cell to either the monocyte or the DC lineage. When taking an
unbiased approach and analyzing the entire transcriptome of the
2 monocyte subsets (classical CD14CD16 and nonclassical
CD14CD16) compared with 3 types of DCs (HLA-DR
positive cells negative for markers of other leukocyte lineages)
in human blood, then hierarchical clustering shows that 3 blood
DC populations cluster together and are clearly separated in their
expression profile from the 2 monocyte populations.9 Therefore,
we can group the 3 cells of the DC lineage together and can assign
them collectively to the DC lineage.
Still, these blood cells do not have typical characteristics of
DCs as seen in tissue. It is apparent that they lack dendrites and also
lack markers of mature DCs such as CD83. In addition, in blood
they most likely do not present antigen to T cells, because this
would require close cell-cell contacts, which is unlikely to occur
under flow conditions. Rather, these DC lineage cells appear to
be in transit, and they mature into functional DCs only after
entering the tissue.
So far, 3 cell types assigned to the DC lineage have been
identified in human blood. Among these the plasmacytoid
DC subset might be addressed as being at an immature DC stage
rather than a precursor, because they have properties of circulating
sentinel cells that, after receiving a maturation signal such as virus
contact, can enter the lymph node through high endothelial venules
to prime T cells immediately.47 By contrast, the CD1c and
CD141 DC lineage cells show features of both DC precursors
(“preDCs”) and of immature DCs. Similar to immature DCs they
have the potential to act as sentinel cells because in vitro they
secrete cytokines when activated, they effectively stimulate T cells,
and they rapidly mature in response to TLR agonists.48,49 However,
the CD1c and CD141 DC lineage cells fail to mature in response
to TNF, and they express early myeloid markers such as CD33 at
high levels, features that would suggest a classification as
DC precursors.48,50 A nomenclature that reflects such distinct
maturational stages of the DCs in blood would be confusing.
Therefore, the panel agreed on the term “blood DCs” for the entire
collection of cells. This terminology goes along with the connota-
tion that a blood DC is not a mature cell of this lineage.
Human DC lineage cells
For human DC lineage cells in blood a subdivision into 3 subsets is
suggested, that is, plasmacytoid DCs and 2 types of myeloid DCs.
Plasmacytoid DCs in tissues were originally described as
T-associated plasma cells, plasmacytoid T cells, or plasmacytoid
monocytes.51-53 When these cells were first isolated from human
tonsils, they were shown to have the ability to differentiate into
mature DCs in culture with interleukin-3.54 In parallel research a
subpopulation of human blood cells, enriched in cells expressing
MHC class II and CD4, was found to have the capacity to produce
high levels of interferon  (IFN-) in response to viruses, and these
cells were named natural type 1 IFN-producing cells.55,56 In crucial
experiments it was shown that these IFN-producing cells are, in
fact, the plasmacytoid DCs.47,57 The CD68 marker can discriminate
the plasmacytoid DCs from the 2 types of myeloid DCs, but this
requires combination with additional markers because CD68 is also
strongly expressed on monocytes.58 While CD123 expression is
only incrementally higher on plasmacytoid DCs compared with
monocytes, CD303 is a marker with good signal-to-noise ratio for
the plasmacytoid DCs.59
Both the CD1c and CD141 myeloid blood DCs express
myeloid markers CD13 and CD33, suggesting their direct deriva-
tion from the myeloid lineage. Although earlier studies relied on
exclusion of all other lineages of leukocytes combined with
high-level MHC class II expression to study these blood DCs, the
CD1c and CD141markers available now only require exclusion of
a few cell types that coexpress these markers.
For proper identification of the CD1c DCs in blood,
CD19CD20 B cells need to be excluded, because the latter cells
also show strong expression of the CD1c molecule. A fraction of
the CD1c blood DCs expresses low-level CD14.60 No compara-
tive data are available on the CD14 and CD14 subsets of the
CD1c cells at this time. In support of their uniqueness functional
studies on CD1c cells have shown a specific pattern of chemokine
production in these cells.61
The CD141 DCs represent a very minor subset of blood
leukocytes. Costaining with CD14 is recommended to exclude
low-level signals from monocytes. These CLEC9ACD141 cells
(but not CD1c blood DCs) are also major producers of IFN-
and cross-present antigen for CD8 class 1–restricted cytotoxic
T lymphocyte responses in response to TLR-3/CD283 ligation.
These and their other properties suggest that they are homologous
to the mouse CD8 DC subset.62-65
It is recommended that the CD1c and CD141 blood DCs are
defined separately and are not addressed as one population of
myeloid blood DCs.
Taken together, we recommend to define human blood DCs as
MHC class II–positive, lineage marker–negative cells and to
subdivide them into 3 subtypes. These are the plasmacytoid
CD303 DCs, the myeloid CD1c DCs, and the myeloid CD141
DCs (Table 2).
Mouse DC lineage cells
For mouse DC lineage cells in blood little information is available.
Still, a subdivision into plasmacytoid and myeloid DCs appears
to emerge.
For plasmacytoid DCs blood cells with a high capacity to
produce IFN- in response to cytosine-phosphate-guanosine stimu-
lation have been defined as CD11clow, CD11b, CD45RAhigh
cells.66 Anti–bone marrow stromal cell Ag 2 (BST2) antibodies
have been described to stain mouse plasmacytoid DCs in spleen,
and staining of mouse blood cells has shown a strong signal for
BST2.67,68 However, expression of the BST2 antigen on plasma
cells under steady state conditions and on many other cells after
induction by type I IFN needs to be considered.
Table 2. Nomenclature of blood dendritic cells
Human Mouse
Plasmacytoid CD303 blood DCs Plasmacytoid blood DCs
Myeloid CD1c blood DCs Myeloid blood DCs
Myeloid CD141 blood DCs Myeloid blood DCs
The CD markers given are considered most appropriate at this time. They may be
superseded by superior reagents in the future. CD303 is the official name for the
commercial antibody BDCA-2, CD1c is BDCA-1, and CD141 is BDCA-3.
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Looking at myeloid DCs the CD11cCD11bCD45RA
cells identified in mouse blood share features with the splenic
CD8 DC subset,66 and they may be homologous to human
CD1c myeloid blood DCs.9
The CLEC9A DC in mouse blood also stain for CD24 and
may thus be representative for the CD8 splenic DC subset.
Because anti-CLEC9A also strongly stains the human blood
CD141 cells65 and because human CD141 blood DCs and mouse
CD8 spleen DCs share specific transcriptional signatures,9 the
CLEC9A mouse blood DCs are potential homologues of the
human CD141CLEC9A myeloid blood DCs. Taken together, it
is clear that there are plasmacytoid and 2 types of myeloid DCs in
mouse blood, but the optimum markers await to be defined.
Therefore, the nomenclature proposal for the mouse does not give
identifying markers at this time (Table 2). For the time being, it is
suggested to define the myeloid subsets with the compilation of
markers, for example, mouse myeloid CD11cCD11bCD45RA
blood DCs.
Differentiation of bone marrow plasmacytoid DCs into
CD11bCD45RA myeloid DCs shows the close relationship of
the plasmacytoid and myeloid DC types.69 In addition, transcrip-
tional profiling and hierarchical clustering of mouse spleen
DCs have shown that the mouse plasmacytoid DCs and the
CD8 and CD8 DCs cluster together in a manner similar to what
has been shown for human blood DCs. In addition, the same
analysis showed coclustering of the human and mouse plasmacy-
toid DCs.9 For further consolidation of the mouse blood DCs it will
be important to analyze expression of orthologues of informative
human cell-surface markers. In addition, transcriptional profiling of
purified mouse blood DCs is required for comparison to humans.
Taken together, we recommend to define mouse blood
DCs similar to humans and to subdivide them into 3 subtypes.
These are the plasmacytoid DCs and 2 types of myeloid
DCs. Because specific markers for these cells in mouse blood are
still to be identified, they currently have to be defined with the use
of combinations of cell-surface markers.
For rat DC lineage cells in blood no data are currently available.
It is expected that homologues of the 3 types of human blood
DCs can be defined in the future with the use of reagents that target
the same or novel DC-specific molecules.
Technical aspects
The analysis of monocytes and blood DCs requires special
attention because the frequency of some of these cells can be
very low. Therefore, contamination of the population of interest by
unwanted events needs to be excluded. For flow cytometric
analysis, we, therefore, suggest to use unprocessed blood,
exclusion of dead cells, gating on CD45, and no gating on scatter
whenever possible and to use reagents with high signal to noise
ratio. In addition, high numbers of total events need to be
acquired to obtain sufficient numbers of specific events for a
meaningful analysis.
When reporting on monocytes and blood DCs in lectures and
publications, we recommend that flow cytometric plots of represen-
tative examples are given initially in the paper or as supplementary
data in online publications, and these need to define the cells based
on isotype controls to show the signal compared with noise. For
optimum assessment the isotype control and the specific antibody
need to be derived from the same manufacturing process with the
same fluorochrome-to-protein ratio. For multicolor flow cytometric
analysis the “fluorescence minus one” principle needs to be
followed, that is, only one antibody is exchanged for an isotype
control at a time.70
Conclusion
The present nomenclature proposal avoids the use of functional
terms such as “proinflammatory” for monocyte and blood
DC subpopulations. Such terms may be stimulating and make
integration of the cells into mechanistic concepts easier. However,
such a nomenclature can lead our thinking and our research into
wrong directions such that we disregard anti-inflammatory proper-
ties of a cell dubbed proinflammatory. Therefore, a neutral nomen-
clature is proposed for monocytes and blood DCs.
For monocyte subpopulations the classical versus intermediate
and nonclassical nomenclature allows for other markers to be used
for the 3 subsets in the future. When new markers are used for
human monocyte subsets then their validity needs to be shown with
reference to the CD14 and CD16 dot plots, and a combination with
these established markers is always recommended. The same
applies to Ly6C and CD43 dot plots in the mouse. In addition, the
nomenclature proposal for blood DCs is open to additional
subpopulations.
At this stage the nomenclature applies to humans and mouse. It
may be applicable directly to nonhuman primates, but for the
bovine, porcine, and rat systems much more experimental work is
needed. We expect that the comprehensive analysis of gene
expression (transcriptome, proteome, metabolome, etc) in subpopu-
lations of blood monocytes and of blood DCs will refine this
nomenclature and will help in consolidating homologues in the
different species.
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